Nevertheless, some NSCLC patients with high levels of tumor PD-L1 have poor responses and, vice versa, patients with low or even negative PD-L1 expression exhibit good and durable responses to checkpoint inhibitors [18,19,20]. This evidence concerns the gene CD274 and neoplasm.